Cover Image

EMB ‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jing Gao, Xi Jiao, Fang Ren, Xuan Wu, Jingyun Tan, Yuezong Bai, Yan Dai, Lixia Shen, Chengbin Wu, Lin Shen
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Cancer Science
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities
by: Rafik ElBeblawy, et al.
Published: (2025)

Efficacy and Safety of EGF / EGFR Vaccines in EGFR ‐Driven Solid Tumors: A Systematic Review and Meta‐Analysis of Controlled and Single‐Arm Studies
by: Fei Chen, et al.
Published: (2025)

Safety, Pharmacokinetics, and Pharmacodynamics Evaluation of Ivonescimab, a Novel Bispecific Antibody Targeting PD‐1 and VEGF, in Chinese Patients With Advanced Solid Tumors
by: Fenghua Wang, et al.
Published: (2025)

Tumor‐Derived Extracellular Vesicles in Plasma for Predicting Anti‐ PD ‐1 Antibody Efficacy in Non‐Small Cell Lung Cancer
by: Tomonari Kinoshita, et al.
Published: (2026)

Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial
by: Ming Bai, et al.
Published: (2025)

Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab‐117 Against Human Tumors
by: Tomohiro Tanaka, et al.
Published: (2025)

Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers
by: Teng Wei, et al.
Published: (2025)

Longitudinal Monitoring of GRIm and HCC ‐ GRIm Scores Reveals Immunologically Relevant Prognostic Indicators in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti‐ VEGF Antibodies/ TKIs
by: Lihao Qin, et al.
Published: (2026)

Stanniocalcin 2‐Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK /Beclin 1 Signaling
by: Yi‐Nan Liu, et al.
Published: (2026)

Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
by: Leah Lawrence
Published: (2026)

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations
by: Yuko Iida, et al.
Published: (2026)

Anti‐angiogenesis in colorectal cancer therapy
by: Zhenni Yang, et al.
Published: (2024)

Thoracic radiotherapy synergizes with first‐line EGFR ‐ TKIs in advanced EGFR ‐mutant NSCLC : A dual‐center real‐world study
by: Zhuoying Tian, et al.
Published: (2025)

Multi‐Transcriptomic Analysis Reveals That EREG ‐Driven TME Crosstalk Defines Anti‐ EGFR Response in Colorectal Cancer
by: Atsuki Taniguchi, et al.
Published: (2026)

TGF ‐β Inhibitor Potentiates Osimertinib‐Induced Anti‐Tumor Immunity in Egfr ‐Mutant Lung Cancer
by: Tadahiro Kuribayashi, et al.
Published: (2026)

Search for Mutations Connected With Non‐Response to Anti‐ EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours
by: Martina Čarnogurská, et al.
Published: (2025)

Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
by: Zi‐Ting Chang, et al.
Published: (2025)

Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy
by: Fayuan Wang, et al.
Published: (2025)

Activation of cGAS ‐ STING Pathway by DAI ‐Triggered Ferroptosis in CRC Cells Reprograms TAMs Balance to Promote Anti‐Tumor Immunity
by: Pengrui Cheng, et al.
Published: (2025)

Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
by: Fengwu Lin, et al.
Published: (2025)

Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach
by: Zhiying Gao, et al.
Published: (2025)

Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan
by: Anna Fleischer, et al.
Published: (2025)

Tumor Anti‐Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment
by: Yu Tang, et al.
Published: (2026)

More treatment options emerge for EGFR ‐mutant NSCLC
by: Leah Lawrence
Published: (2026)

Current Knowledge of Immune Checkpoint Inhibitor‐Induced Thrombocytopenia: Epidemiology, Mechanisms, and Management
by: Youran Dai, et al.
Published: (2026)

Lung Adenocarcinoma With Initially Co‐Occurring EGFR and BRAF Double Mutation: A Case Report and Literature Review
by: Lu Wang, et al.
Published: (2025)

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial
by: Huiyang Shi, et al.
Published: (2025)

Advancements in Inorganic Chiral Nanomaterials for Anti‐Tumor Immunotherapy
by: Siyu Chen, et al.
Published: (2026)

Research on Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Therapy in cN1 Breast Cancer Patients
by: Jiabei Shang, et al.
Published: (2026)

Clinical Outcomes of Later‐Generation EGFR ‐ TKIs for Uncommon EGFR Mutations in NSCLC : A Multicenter Real‐World Study
by: Lisa Shigematsu, et al.
Published: (2025)

Loss of Tapasin in Tumors Potentiates T‐Cell Recognition and Anti‐Tumor Effects of Immune Checkpoint Blockade
by: Keigo Moniwa, et al.
Published: (2025)

Near‐Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti‐ EpCAM Antibody
by: Maasa Sasabe, et al.
Published: (2025)

Anti‐Tumor Activity of Paclitaxel‐Containing Regimens in Recurrent/Refractory Wilms Tumor
by: Alissa Groisser, et al.
Published: (2025)

Safety and Efficacy of Romiplostim in Maintaining Chemotherapy Interval and Dose Intensity in Pediatric Patients With Solid Tumors and Chemotherapy‐Induced Thrombocytopenia
by: Erica Tonti, et al.
Published: (2026)

Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease
by: Chuchu Shao, et al.
Published: (2024)

The Efficacy of Immune Checkpoint Inhibitors in the EGFR Mutant and Wild‐Type Non‐Small Cell Lung Cancer Is Positively Associated With the Maturation and Abundance of Dendritic Cells
by: Fengqi Xiao, et al.
Published: (2025)

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti‐CD38 Monoclonal Antibodies: A Systematic Review
by: Chia Jie Tan, et al.
Published: (2025)

Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC
by: Yidan Zhang, et al.
Published: (2025)

Relationship Between Short‐Term Outcomes and PD‐L1 Expression Based on Combined Positive Score and Tumor Proportion Score in Recurrent or Metastatic Head and Neck Cancers Treated With Anti‐PD‐1 Antibody Monotherapy
by: Akihiro Ohara, et al.
Published: (2025)

Mechanisms Involved in Focal Adhesion Signaling Regulating Tumor Anoikis Resistance
by: Bin Liu, et al.
Published: (2025)